Showing results (21-30 of 26) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Oncology|November 26, 2015
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient dataDidier Meulendijks, Linda M Henricks, Gabe S Sonke, et al.Clinical Pharmacology and Therapeutics|April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyMirjam de With, Jonathan Knikman, Femke M de Man, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair AnalysisJonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.Pageof 3